Back to Market返回行情

OMCL Omnicell, Inc.

USHealthcare
$44.92-1.47%ClosedMarket Cap: $2.04B

As of 2026-07-10 16:00

Why OMCL matters now

Omnicell, Inc. (OMCL) is a US stock in Healthcare. The latest InvestLog snapshot shows $44.92 with -1.47% on the session and $2.04B in market capitalization; recent performance reads 1-month -10.89% and YTD -13.80%.

The latest financial table shown here is Q1 2026, with revenue of $309.9M, net income of $11.4M, and EPS of $0.25. Investors can compare that operating picture with valuation signals such as P/E 763.91 and FCF yield 6.3%.

The latest indexable market news headline is "Should You Continue to Hold OMCL Stock in Your Portfolio Now?" from Zacks Investment Research.

Additional event context on this page matters because analyst consensus is Buy with a median target of $55.00; recent insider activity includes Manley Corey J filing S-Sale. These signals are research inputs, not a recommendation.

Valuation

P/E (TTM)

763.91

PEG

P/B

1.41

P/S

1.45

EV/EBITDA

13.53

DCF Value

$26.67

FCF Yield

6.3%

Div Yield

0.0%

Margins & Returns

Gross Margin

43.5%

Operating Margin

2.8%

Net Margin

1.7%

ROE

1.6%

ROA

1.0%

ROIC

1.2%

Financials

PeriodRevenueNet IncomeEPS
Q1 2026$309.9M$11.4M$0.25
Q4 2025$314.0M$-2.0M$-0.05
FY 2025$1.18B$2.1M$0.04
Q3 2025$310.6M$5.5M$0.12

Analyst Ratings

Consensus

Buy

Target (Consensus)

$57.20

Target (Median)

$55.00

Target Range

$49.00 - $70.00

Strong Buy: 1Buy: 6Hold: 1Sell: 0Strong Sell: 0
KeybancOverweight
2026-04-29
Wells FargoOverweight
2026-04-23
Piper SandlerOverweight
2026-02-06
BenchmarkBuy
2026-02-02
KeybancOverweight
2026-01-08

Trading Activity

Insider Trades

Manley Corey Jofficer: EVP&CHIEF LEGAL/ADMIN OFFICER
Sell2026-05-19
Njoku Nnamdiofficer: EVP, Chief Operating Officer
Sell2026-05-19
LIPPS RANDALL Adirector, officer: CHAIRMAN, PRESIDENT AND CEO
Sell2026-05-19
Manley Corey Jofficer: EVP&CHIEF LEGAL/ADMIN OFFICER
Sell2026-05-19
NUTT BRIAN H.officer: VP, Chief Accounting Officer
Sell2026-05-19

Latest News

Company Info

Sector

Healthcare

Industry

Medical - Healthcare Information Services

Country

US

Exchange

Beta

0.96

Omnicell, Inc., founded in 1992 and headquartered in Mountain View, California (initially operating as Omnicell Technologies, Inc. until its name change in 2001), delivers advanced medication management technologies and patient adherence solutions. The company serves healthcare systems and pharmacies both domestically within the United States and globally. Its extensive portfolio of offerings includes: Clinical Workflow Automation: Omnicell provides automated solutions designed to streamline clinician tasks in patient care environments. This encompasses the XT Series automated dispensing units for medications and supplies across nursing units, clinical areas, and surgical suites. They also offer interface software to ensure smooth integration between their products and a healthcare facility's existing information systems, alongside robotic systems for automated storage and retrieval of packaged medications. Central Pharmacy Optimization: For the central pharmacy, Omnicell offers sophisticated automation, including automated storage and retrieval platforms like the XR2 Automated Central Pharmacy System. This segment also features robotic systems and workflow management tools for IV compounding, comprehensive inventory management software, and systems for controlled substance oversight. Single-Dose Packaging for Adherence: The company develops automated technologies for filling and labeling patient-specific, single-dose medication blister packaging according to prescriptions. This includes both fully and semi-automated equipment for institutional pharmacies to ensure precise packaging, along with blister card packaging and supplies aimed at improving medication adherence, particularly in non-acute care settings. Digital Patient Engagement: Omnicell further provides EnlivenHealth Patient Engagement, a web-based platform offering various tools to interact with patients.